Ironwood Pharmaceuticals, Inc. ( IRWD ) Q3 2026 Earnings Call November 5, 2026 8:30 AM EST Company Participants Chris Stamm - Vice President of Investor Relations & Communications Thomas McCourt - CEO & Director Tammi Gaskins - Senior Vice President & Chief Commercial Officer Jeffrey Silber - Chief Medical Officer, Head of Research & Drug Development Ronald Silver - Senior VP, Interim CFO, Corporate Controller & Chief Accounting Officer Jeff Ruberti - Chief Strategy Officer Conference Call Participants Mohit Bansal - Wells Fargo Securities, LLC, Research Division Nicholas Mattiacci Tom Rosenfeld Presentation Operator Hello, everyone. My name is Megan, and I will be your conference operator today.
Ironwood Pharmaceuticals NASDAQ: IRWD raised its 2026 financial outlook after third-quarter sales of LINZESS reached $325 million, as improved net pricing and prescription demand supported the gastrointestinal drug's performance.
Ironwood Pharmaceuticals (IRWD) came out with quarterly earnings of $0.36 per share, beating the Zacks Consensus Estimate of $0.3 per share. This compares to earnings of $0.24 per share a year ago.
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life‑changing therapies for people living with gastrointestinal (GI) and rare diseases, today reported its third quarter 2026 results and recent business performance update. “Ironwood delivered a third consecutive strong quarter as we continue focused execution of our three strategic priorities: maximize LINZESS, advance apraglutide and deliver sustained profits and cas.
CWA Asset Management Group LLC grew its stake in Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) by 71.7% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 498,643 shares of the biotechnology company's stock after purchasing an additional 208,277 shares during the
BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI) and rare diseases, today announced that its Board of Directors appointed Chief Commercial Officer Tammi Gaskins as Chief Executive Officer and a member of the Board of Directors, effective January 1, 2027. On that date Chief Executive Officer Tom McCourt will retire from his current role and will remai.
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the seven research firms that are presently covering the firm, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating on
Ironwood Pharmaceuticals is rated Buy, but the investment thesis hinges on apraglutide, not Linzess, due to looming generic competition. IRWD's Linzess cash flow is largely committed to debt and taxes, with generics expected by 2029 and Medicare price cuts impacting margins. Apraglutide's value depends on successful STARS-2 trial results and timely approval, with peak sales modeled conservatively at $456 million.